The size of the Europe Blood Testing Market is valued at USD 16.12 billion in 2020 and is estimated to be growing at a CAGR of 2.37% to reach USD 18.12 billion by 2025. The European blood testing market was the second most leading region in the global market due to the growing number of blood transmission methods. An increase in the number of complicated surgeries being implemented, such as chemotherapy, heart surgery, and organ transplant, needs several blood samples to fuel the market growth.
Blood-based diagnostics are vast right now. There are numerous new diagnostics from blood samples coming up, due to research on biomarkers for colorectal cancer, lung cancer, liver disease, and even depression.
Increasing adoption of testing and screening methodologies that improve near-patient diagnosis through better blood testing that decreases diagnostic turnaround time and reduces hospital stay durations is a crucial factor estimated to offer lucrative growth in demand. Technical improvement and development in making new equipment and tools provide excellent opportunities for the European regional market.
Though, lack of awareness and unavailability of expert labor is probable to limit the market growth.
The European Blood Testing Market has been segmented and sub-segmented into the following categories
Based on region, France and the U.K. are the emerging countries for the blood testing market in this region.
The German blood testing market was leading the European market with the highest share and is projected to maintain its position throughout the analysis period. According to WHO, the growth is caused by the increase in awareness regarding blood donation, where the blood donation growth rate has risen from 3.4% to 3.6% from 2008 to 2010. In this country, nearly 2million people are donating blood frequently every year. Moreover, this country directs the blood testing market because of many key players and a high-quality structure for hospitals and clinical laboratories. Reducing the hospital stay duration, which is expected to offer profitable outcomes, technical advancements, and development in enhancing new equipment required for blood testing is expected to boost Europe's market growth.
Countries like France and the UK are developing countries in Europe. The growth in these countries is attributed to the rising adoption of testing and testing methodologies and advanced technologies, availability of practiced and experienced professionals, which fuel the blood testing market growth over the period. Also, increasing infectious diseases, a frequent increase of new pathogens foster growth in this region.
Countries like Spain, Italy, Sweden, Russia, Switzerland, and other countries of this region are predicted to have considerable growth in forthcoming years.
Prominent Companies dominating the Europe Blood Testing Market Profiled in the Report are Bio-Rad Laboratories Inc. (U.S.), Siemens Healthcare (Germany), Grifols (Spain), Nanosphere Inc. (U.S.), BioMérieux (France), Dickinson and Company (U.S.), Ortho Clinical Diagnostics Inc. (U.S.), Roche Diagnostics (Switzerland), Alere Inc. (U.S.), Bruker Corporation (U.S.), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.) and Beckman Coulter (U.S.).
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Complete Blood Count
5.1.1.1 Red Blood Cells
5.1.1.2 White Blood Cells
5.1.1.3 Haemoglobin
5.1.1.4 Hematocrit
5.1.1.5 Platelets
5.1.2 Blood Chemistry Tests
5.1.2.1 Test for Electrolytes
5.1.2.2 Blood Glucose
5.1.2.3 Calcium
5.1.2.4 Test for Kidney Function
5.1.3 Blood Enzyme Tests
5.1.3.1 Troponin
5.1.3.2 Creatine Kinase
5.1.4 Blood Clotting Tests
5.1.4.1 Prothrombin time
5.1.4.2 Activated Partial Thromboplastin time
5.1.4.3 Blood Coagulation
5.2 By Diseases
5.2.1 Anaemia
5.2.2 Infection
5.2.3 Leukaemia
5.2.4 Hypokalemia
5.2.5 Kidney Disorders
5.2.6 Heart Attack
5.2.7 Coronary Heart Disease
5.3 By Methods
5.3.1 Manual Blood Culture Testing
5.3.2 Automated Blood Culture Testing
5.3.2.1 Automated Blood Culture System
5.3.2.2 Blood Culture Instruments
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Bio-Rad Laboratories Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Siemens Healthcare
8.3 Grifols
8.4 Nanosphere Inc.
8.5 BioMérieux
8.6 Dickinson and Company
8.7 Ortho Clinical Diagnostics Inc.
8.8 Roche Diagnostics
8.9 Alere Inc.
8.10 Bruker Corporation
8.11 Abbott Laboratories
8.12 Thermo Fisher Scientific Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
